Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Earnings Preview: What To Expect From Molina Healthcare's Report

With a market cap of $9.7 billion, Molina Healthcare, Inc. (MOH) delivers managed healthcare services to low-income individuals and families. It serves members through Medicaid, Medicare, and state insurance marketplace programs. 

The Long Beach, California-based company is slated to announce its fiscal Q4 2025 results after the market closes on Thursday, Feb. 5. Ahead of the event, analysts expect MOH to report an adjusted EPS of $0.43, down 91.5% from $5.05 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in one of the past four quarterly reports while missing on three other occasions. 

Fundamentals

See More
  • Market Capitalization, $K 220,906,304
  • Shares Outstanding, K 1,738,872
  • Annual Sales, $ 41,950 M
  • Annual Income, $ 13,402 M
  • EBIT $ 9,438 M
  • EBITDA $ 12,656 M
  • 60-Month Beta 0.72
  • Price/Sales 5.03
  • Price/Cash Flow 19.41
  • Price/Book 4.33

Options Overview Details

View History
  • Implied Volatility 25.31% (+1.02%)
  • Historical Volatility 16.10%
  • IV Percentile 81%
  • IV Rank 33.94%
  • IV High 42.50% on 04/07/25
  • IV Low 16.47% on 01/24/25
  • Expected Move (DTE 7) 2.83 (2.24%)
  • Put/Call Vol Ratio 0.92
  • Today's Volume 4,936
  • Volume Avg (30-Day) 7,689
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 205,658
  • Open Int (30-Day) 199,161
  • Expected Range 123.35 to 129.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.50
  • Number of Estimates 9
  • High Estimate 1.51
  • Low Estimate 1.49
  • Prior Year 1.34
  • Growth Rate Est. (year over year) +11.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.70 +4.54%
on 12/10/25
129.64 -2.67%
on 12/15/25
+4.09 (+3.35%)
since 12/08/25
3-Month
120.70 +4.54%
on 12/10/25
135.13 -6.62%
on 10/09/25
-8.09 (-6.03%)
since 10/08/25
52-Week
110.86 +13.82%
on 01/15/25
141.23 -10.66%
on 03/04/25
+11.93 (+10.44%)
since 01/08/25

Most Recent Stories

More News
1 S&P 500 Stock to Consider Right Now and 2 We Turn Down

1 S&P 500 Stock to Consider Right Now and 2 We Turn Down

ABT : 126.18 (-0.68%)
ALGN : 170.58 (+2.26%)
IQV : 243.19 (-0.45%)
Earnings Preview: What To Expect From Molina Healthcare's Report

Molina Healthcare is expected to unveil its fourth-quarter results next month, and analysts expect a double-digit decrease in earnings.

ABT : 126.18 (-0.68%)
XLV : 158.12 (-0.96%)
$SPX : 6,921.46 (+0.01%)
MOH : 183.50 (+4.04%)
Abbott hosts conference call for fourth-quarter earnings

ABBOTT PARK, Ill. , Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

ABT : 126.18 (-0.68%)
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

ABBOTT PARK, Ill. , Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled  Libre Assist , 1 a groundbreaking feature within the Libre app 5 designed...

ABT : 126.18 (-0.68%)
What You Need To Know Ahead of Quest Diagnostics' Earnings Release

Quest Diagnostics is expected to unveil its fourth-quarter results soon, and analysts expect a single-digit growth in earnings.

ABT : 126.18 (-0.68%)
XLV : 158.12 (-0.96%)
DGX : 177.74 (-0.22%)
$SPX : 6,921.46 (+0.01%)
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?

Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?

ABT : 126.18 (-0.68%)
What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

ABT : 126.18 (-0.68%)
XLV : 158.12 (-0.96%)
$SPX : 6,921.46 (+0.01%)
This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

ABT : 126.18 (-0.68%)
Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength

Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds.

NAT : 3.90 (+3.72%)
MSFT : 478.11 (-1.11%)
ABT : 126.18 (-0.68%)
AVGO : 332.48 (-3.21%)
Abbott's Voltâ„¢ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

ABBOTT PARK, Ill. , Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Voltâ„¢ PFA System to treat patients battling...

ABT : 126.18 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 129.54
2nd Resistance Point 128.82
1st Resistance Point 127.50
Last Price 126.18
1st Support Level 125.46
2nd Support Level 124.74
3rd Support Level 123.42

See More

52-Week High 141.23
Fibonacci 61.8% 129.63
Last Price 126.18
Fibonacci 50% 126.04
Fibonacci 38.2% 122.46
52-Week Low 110.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar